With replacement shelved, regulations could decide ACA’s fate

The Republican-controlled House couldn’t pass a replacement for the Affordable Care Act, but if the goal is to weaken the law, the executive branch can do so all on its own.

As explained by Reuters, HHS Secretary Tom Price can roll back many of the underlying ACA regulations. He’s already done so on other healthcare polices, like delaying the start of mandatory bundled payment models finalized in the last days of the Obama administration.

If Price uses his administrative powers to target the ACA or the Medicare Access and CHIP Reauthorization Act (MACRA), both insurance market stability and the transition to value-based care could be affected.

Read the full article below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.